New Challenge Pool of Norwalk Virus Inoculum
NCT00138476 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 57
Last updated 2014-05-09
Summary
The main objective of this study is to see the number of volunteers that get sick from a Norwalk virus (NV) inoculation with typical symptoms of nausea, vomiting, and diarrhea. If this NV preparation is shown to cause Norwalk illness, then it can be used to test new vaccines in the future. Additionally, researchers hope to determine the lowest dose of NV inoculum that can be given to volunteers and cause illness. Study participants will include 57 healthy adults, ages 18-50. Participants will either be given the NV inoculum or placebo (water without virus). Participants will be hospitalized for a maximum of 7 days and a minimum of 4 days following the NV challenge. Study procedures include physical exam, blood testing, and collection of saliva, urine, and stool samples. Participants will be involved in study related procedures for up to 180 days.
Conditions
- Gastroenteritis Norovirus
Interventions
- DRUG
-
120 mL of the sodium bicarbonate solution, followed by 82 mL of sterile water, United States Pharmacopeia (USP) without virus; followed by 500 mg of sodium bicarbonate aqueous solution taken 5 minutes after placebo inoculation.
- BIOLOGICAL
-
Norwalk Virus
Prepared and packaged from liquid feces (DC544) by clarification, centrifugation, and serial dilutions; desired doses \[reverse transcription polymerase chain reaction (RT-PCR) Units\] 4800, 48, 4.8, 0.48.
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Study Design
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2004-08-31
- Primary Completion
- 2012-04-30
- Completion
- 2012-09-30
Countries
- United States
Study Locations
More Related Trials
-
Infectivity of Norovirus in Groundwater-Human Challenge Study
NCT00313404 ·Status: COMPLETED ·Phase: NA
-
Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine
NCT04854746 ·Status: COMPLETED ·Phase: PHASE1
-
Topical Capsaicin for Cyclical Vomiting
NCT03223350 ·Status: COMPLETED ·Phase: PHASE2
-
Applying Nutrient Drink Test in Understanding Pathophysiology of CVS
NCT03470181 ·Status: COMPLETED
-
Efficacy and Safety of the Administration of Ondansetron Versus Habitual Clinical Practice for the Treatment of Vomiting in Children With Mild and Moderate Dehydration: Randomized Clinical Trial
NCT04318847 ·Status: UNKNOWN ·Phase: PHASE4
-
Oral Disintegrating Ondansetron Tablet to Reduce Vomiting From Gastroenteritis in a Pediatric Emergency Department
NCT00120744 ·Status: COMPLETED ·Phase: NA
-
Haloperidol for the Treatment of Nausea and Vomiting in the ED
NCT04764344 ·Status: COMPLETED ·Phase: PHASE4
-
Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial
NCT01149369 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of TAK-951 in Healthy Adults
NCT04486950 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of TAK-105 in Healthy Adults
NCT04964258 ·Status: COMPLETED ·Phase: PHASE1
-
Pedialyte or Gatorade for Viral Gastroenteritis in Adults: a Randomized, Controlled Trial
NCT00257374 ·Status: COMPLETED ·Phase: NA
-
Randomized Trial of the Effectiveness of Topical "ABH Gel" vs. Placebo in Cancer Patients With Nausea
NCT01556932 ·Status: COMPLETED ·Phase: NA
-
Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting
NCT02473887 ·Status: COMPLETED ·Phase: PHASE1
-
Ondansetron Versus Metoclopramide in Treatment of Vomiting in Gastroenteritis
NCT01165866 ·Status: COMPLETED ·Phase: PHASE4
-
Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide
NCT06740812 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Thumbtack Needle in the Treatment of NVP
NCT06566274 ·Status: RECRUITING ·Phase: NA
-
Vestibular Dysfunction as a Cause of Chronic Nausea & Vomiting: A Follow up Survey
NCT01378351 ·Status: TERMINATED
-
To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Fasting Conditions
NCT00946387 ·Status: COMPLETED ·Phase: PHASE1
-
Uncomplicated Nausea and Vomiting in the Emergency Department
NCT00778011 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy Study of IV Fluids Only vs Ondansetron to Treat Dehydration
NCT00691275 ·Status: WITHDRAWN ·Phase: NA
-
Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion
NCT04947423 ·Status: COMPLETED ·Phase: PHASE3
-
Multi-DOSE Oral Ondansetron for Pediatric Acute GastroEnteritis
NCT03851835 ·Status: COMPLETED ·Phase: PHASE3
-
Galvanic Vestibular Stimulation as a Novel Treatment for Seasickness
NCT05004818 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion
NCT05548270 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Meclizine Orodispersible Tablet Pharmacokinetic in Human Volunteers
NCT04564144 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2